tetano
Editor, Senior Moderator
Transpl Infect Dis
. 2022 Jan 5.
doi: 10.1111/tid.13788. Online ahead of print.
COVID-19 vaccination is protective of clinical disease in solid organ transplant recipients
Saima Aslam[SUP] 1 [/SUP], Jinyuan Liu[SUP] 1 [/SUP], Rachel Sigler[SUP] 1 [/SUP], Rehan R Syed[SUP] 1 [/SUP], Xin M Tu[SUP] 1 [/SUP], Susan J Little[SUP] 1 [/SUP], Victor De Gruttola[SUP] 2 [/SUP]
Affiliations
Abstract
Background: Clinical effectiveness of coronavirus disease 2019 (COVID-19) vaccination in solid organ transplant recipients (SOTR) is not well documented despite multiple studies demonstrating sub-optimal immunogenicity.
Methods: We reviewed medical records of eligible SOTRs at a single center to assess vaccination status and identify cases of symptomatic COVID-19 from 1/1/2021-8/12/2021. We developed a Cox proportional hazards model using date of vaccination and time since transplantation as a time varying covariate with age and gender as potential time-invariant confounders. Survival curves were created using the parameters estimated from the Cox model.
Results: Among 1904 SOTRs, 1362 were fully vaccinated (96% received mRNA vaccines) and 542 were either unvaccinated (n = 470) or partially vaccinated (n = 72). There were 115 cases of COVID-19, of which 12 occurred in fully vaccinated individuals. Cox regression with date of vaccination and time since transplantation as the time-varying co-variates showed that after baseline adjustment for age and sex, being fully vaccinated had a significantly lower hazard for COVID-19, hazard ratio = 0.29, 95% confidence interval (0.09, 0.91).
Conclusion: We found that 2-dose mRNA COVID-19 vaccination was protective of symptomatic COVID-19 in vaccinated vs. unvaccinated SOTRs.
Tweet: COVID-19 vaccination was associated with significantly lower hazard for symptomatic COVID-19 (HR 0.29, 95% CI 0.09, 0.91) among 1904 SOT recipients at a single center from 1/1/2021-8/12/2021. This article is protected by copyright. All rights reserved.
Keywords: COVID-19 vaccine; SARS-CoV-2; clinical effectiveness; solid organ transplant.
. 2022 Jan 5.
doi: 10.1111/tid.13788. Online ahead of print.
COVID-19 vaccination is protective of clinical disease in solid organ transplant recipients
Saima Aslam[SUP] 1 [/SUP], Jinyuan Liu[SUP] 1 [/SUP], Rachel Sigler[SUP] 1 [/SUP], Rehan R Syed[SUP] 1 [/SUP], Xin M Tu[SUP] 1 [/SUP], Susan J Little[SUP] 1 [/SUP], Victor De Gruttola[SUP] 2 [/SUP]
Affiliations
- PMID: 34989104
- DOI: 10.1111/tid.13788
Abstract
Background: Clinical effectiveness of coronavirus disease 2019 (COVID-19) vaccination in solid organ transplant recipients (SOTR) is not well documented despite multiple studies demonstrating sub-optimal immunogenicity.
Methods: We reviewed medical records of eligible SOTRs at a single center to assess vaccination status and identify cases of symptomatic COVID-19 from 1/1/2021-8/12/2021. We developed a Cox proportional hazards model using date of vaccination and time since transplantation as a time varying covariate with age and gender as potential time-invariant confounders. Survival curves were created using the parameters estimated from the Cox model.
Results: Among 1904 SOTRs, 1362 were fully vaccinated (96% received mRNA vaccines) and 542 were either unvaccinated (n = 470) or partially vaccinated (n = 72). There were 115 cases of COVID-19, of which 12 occurred in fully vaccinated individuals. Cox regression with date of vaccination and time since transplantation as the time-varying co-variates showed that after baseline adjustment for age and sex, being fully vaccinated had a significantly lower hazard for COVID-19, hazard ratio = 0.29, 95% confidence interval (0.09, 0.91).
Conclusion: We found that 2-dose mRNA COVID-19 vaccination was protective of symptomatic COVID-19 in vaccinated vs. unvaccinated SOTRs.
Tweet: COVID-19 vaccination was associated with significantly lower hazard for symptomatic COVID-19 (HR 0.29, 95% CI 0.09, 0.91) among 1904 SOT recipients at a single center from 1/1/2021-8/12/2021. This article is protected by copyright. All rights reserved.
Keywords: COVID-19 vaccine; SARS-CoV-2; clinical effectiveness; solid organ transplant.